Segment reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Segment Loss Including Segment Expenses

The table below is a summary of the segment loss, including significant segment expenses (in thousands):

	Twelve months ended December 31,
	2024			2023			2022
Operating expenses:
Research and laboratory	$	51,133		$	85,197		$	105,482
Technical operations and manufacturing		39,713			52,359			55,621
Clinical development		35,389			27,370			22,093
Facility costs		49,429			54,778			49,186
Support functions		45,587			54,355			51,390
Stock-based compensation		37,678			35,533			36,397
Portfolio prioritization costs		5,840			5,203			8,704
Other(1)		16,835			27,327			28,573
Research and development related success payments and contingent consideration		(8,881	)		(48,981	)		(84,882	)
Total operating expenses		272,723			293,141			272,564
Loss from operations		(272,723	)		(293,141	)		(272,564	)
Interest income, net		10,471			9,938			3,762
Other expense, net		(4,507	)		(52	)		(674	)
Net loss	$	(266,759	)	$	(283,255	)	$	(269,476	)

(1) Other segment expenses includes licensing costs, consulting fees, business taxes, insurance costs, impairment of certain lab equipment and leasehold improvements for the years ended December 31, 2024 and 2023, and costs incurred for the early termination of the Fremont lease for the year ended December 31, 2023.